Roche YTD September 2017 salesbf6a0b14-e682-4af8-b4e1-7cc59c2e23… · 3 This presentation contains...
Transcript of Roche YTD September 2017 salesbf6a0b14-e682-4af8-b4e1-7cc59c2e23… · 3 This presentation contains...
3
This presentation contains certain forward-looking statements. These forward-looking
statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’,
‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among
other things, strategy, goals, plans or intentions. Various factors may cause actual results to
differ materially in the future from those reflected in forward-looking statements contained in
this presentation, among others:
1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.
Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to
mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily
match or exceed the historical published earnings or earnings per share of Roche.
For marketed products discussed in this presentation, please see full prescribing information on our website
www.roche.com
All mentioned trademarks are legally protected.
YTD Sept 2017: Strong sales growth in both
divisions
6 CER=Constant Exchange Rates
2017 2016
CHFbn CHFbn CHF CER
Pharmaceuticals Division 30.6 29.1 5 5
Diagnostics Division 8.8 8.4 5 5
Roche Group 39.4 37.5 5 5
Change in %
YTD Sept 2017: Strong sales growth in US and
International
7
0
2
4
6
8
10
12
14
16
18
Japan International Europe US
Diagnostics
Pharma
CHFbn
+10%
-2% +4%
+2%
+1% +14%
+1%
-1%
+8%
-1%
+2%
+7%
All growth rates at Constant Exchange Rates (CER)
Q3 2017: Sales growth for the sixth consecutive
year
8
2%
6%
4%
6% 6%
4%
8%
7%
5%
4%
5%
6%
5%
7%
6%
4% 4%
6%
3% 3%
4%
6% 6%
0%
2%
4%
6%
8%
10%
Q1
12
Q2
12
Q3
12
Q4
12
Q1
13
Q2
13
Q3
13
Q4
13
Q1
14
Q2
14
Q3
14
Q4
14
Q1
15
Q2
15
Q3
15
Q4
15
Q1
16
Q2
16
Q3
16
Q4
16
Q1
17
Q2
17
Q3
17
All growth rates at Constant Exchange Rates (CER)
YTD Sep 2017: Successful launch activities
Differentiation driving growth
9
• EU: Positive CHMP opinion in 1L ALK+ NSCLC
• US: 1L under FDA priority review and listing in NCCN
guidelines as category 1 preferred option
• EU approval in bladder (1/2L) & lung (2L)
• Approved in RMS & PPMS: US, CH, Australia
• Positive early feedback from all stakeholders
Additional sales
of recent launches
+900m
Ocrevus
+500m
Alecensa
+122m
Tecentriq
+278m
CHF
PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=National Comprehensive Cancer Network;
CHMP=Committee for Medicinal Products for Human Use
Total:
Q3 2017: Sustainable Roche business case
Important milestones achieved
10
HER2 franchise Perjeta in adjuvant BC (APHINITY) US priority review, EU filed
CD20/Hematology
Gazyva in 1L iNHL (GALLIUM)
Venclexta in R/R CLL (MURANO)
Polatuzumab in R/R DLBCL (Ph II)
US priority review, EU approved
Ph 3 met primary endpoint
BTD, EU PRIME designation
Cancer Immunotherapy Tecentriq EU approved in bladder and lung
Lung cancer Alecensa in 1L ALK+ NSCLC US priority review, positive CHMP opinion
Hemophilia A Emicizumab in inhibitors
(HAVEN 1 and 2)
BTD, US priority review, EU accelerated
assessment
Neuroscience Ocrevus Additional approvals in AUS, CAN, CH
Spinal Muscular Atrophy SMN2 splicer (SUNFISH) Ph 1b at WMS* – Pivotal Ph III initiated
* WMS=World Muscle Society, October 2017; BTD=breakthrough therapy designation
Roche significantly advancing patient care
Recognition for innovation 2013-present
11
Rank Company #
1 Roche 18
2 Novartis 15
3 BMS 10
4 Merck 9
4 Pfizer 9
18 Breakthrough Therapy Designations
Source: http://www.focr.org/breakthrough-therapies as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine;
AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating
agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis
Aiming to set new standards of care
Upcoming readouts for CIT & Hematology
13
Readouts:
(Q4 17 to Q2 18)
Most comprehensive lung cancer program
addressing all common backbones Lung
5 trials in non-squamous,
squamous & small cell
lung cancer
Among the leaders in renal cancer GU 1L RCC
First-in-class in colorectal cancer CRC 2/3L CRC
First-in-class in triple negative breast cancer Breast 1L TNBC
First-in-class in non-inhibitor hemophilia A Hemophilia Non-inhibitors and
monthly schedule
2017 outlook raised at HY
15
Group sales growth1 Mid-single digit
Core EPS growth1 Broadly in line with sales growth
Dividend outlook Further increase dividend in Swiss francs
1 At Constant Exchange Rates (CER)
YTD Sept 2017: Pharma sales
Strong growth in US due to ongoing launches
18 CER=Constant Exchange Rates
2017 2016
CHFm CHFm CHF CER
Pharmaceuticals Division 30,636 29,140 5 5
United States 15,266 13,850 10 10
Europe 6,766 6,916 -2 -2
Japan 2,675 2,690 -1 2
International 5,929 5,684 4 4
Change in %
YTD Sept 2017: Strong sales performance with
increasing contribution from new launches
19 Absolute values and growth rates at Constant Exchange Rates (CER)
-250 -150 -50 50 150 250 350 450 550
Tarceva
Avastin
Tamiflu
Pegasys
Lucentis
Esbriet
Activase/TNKase
Herceptin
Alecensa
MabThera/Rituxan
Actemra/RoActemra
Xolair
Perjeta
Tecentriq
Ocrevus
US
Europe
Japan
International-17%
+357%
+17%
+17%
+13%
+102%
+2%
-2%
-21%
+14%
CHFm
-36%
+11%
+2%
n/a
+4%
0 5 10
Cotellic +
Zelboraf
Alecensa
Tecentriq
Tarceva
CD20
Avastin
HER2
Perjeta
Herceptin
Kadcyla
+6%
-2%
-17%
+357%
+3%
Gazyva/Gazyvaro
Cotellic
MabThera/Rituxan
(Oncology)
-12%
+102%
20
YTD Sept 2017: Oncology with +3% growth
CHFbn
YoY CER growth
YTD Sept 2017 Oncology sales: CHF 19.2bn; All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy;
FL=follicular lymphoma; NCCN=National Comprehensive Cancer Network
• Increased competition
• Breast cancer reimbursement in France,
• CIT competition in US
• Perjeta: Strong growth in all regions
• Kadcyla: Growth driven by International, US, and EU
• US: Cotellic+Zelboraf stable 1/2L market share
• EU: Cotellic+Zelboraf increasing; Zelboraf mono declining
• US: NCCN category 1 listing in 1L as preferred option
• US/EU: 1L filing completed (Positive CHMP opinion)
• EU: Approval in lung (2/3L) and bladder (2L and 1L
cisplatin ineligible) achieved
• US: Gazyva in 1L FL (GALLIUM) on NCCN guidelines
• EU: Approval in 1L FL achieved
HER2 franchise: Growth driven by Perjeta and
Kadcyla
0
500
1,000
1,500
2,000
2,500
Q3 14 Q3 15 Q3 16 Q3 17
Herceptin Perjeta Kadcyla
+23%
YoY CER growth
+8%
+16%
CER=Constant Exchange Rates; BC=breast cancer; SC=subcutaneous
CHFm +5%
HER2 franchise Q3 2017
• Perjeta (+17%): Strong demand in
neoadj. and 1L BC driven by all regions
• Kadcyla (+10%): Growth in International,
US and EU
Outlook 2017
• US: Priority review for APHINITY (adj.
BC) with PDUFA date set for Jan 28
• EU filing of APHINITY completed
21
Immunology: Differentiation and new indications
contributing to strong growth
22
0
400
800
1,200
1,600
2,000
Q3 14 Q3 15 Q3 16 Q3 17
MabThera/Rituxan (RA) Actemra IVActemra SC XolairCellCept PulmozymeEsbriet Other
CHFm
CER=Constant Exchange Rates; CRS=cytokine release syndrom; GPA=granulomatosis with polyangiitis; MPA=microscopic polyangiitis
YoY CER growth
+15%
+23% +10%
+8% Immunology Q3 2017
Xolair (+17%)
• Asthma: US pediatrics launch ongoing;
only biologic approved for children
Actemra (+13%)
• EU approval in giant cell arteritis
• US approval for CRS
MabThera/Rituxan (+6%)
• Continues to grow in rheumatoid
arthritis and vasculitis (GPA and MPA)
23 DR=diabetic retinopathy; mCNV=myopic choroidal neovascularisation; wAMD=wet age-related macular degeneration; DME=diabetic
macular edema; MoA=mechanism of action
Lucentis Q3 2017
• US (+8%): Growth driven by prefilled
syringe and new indications DR and
mCNV
Outlook 2017/18
• Overall FY growth expected
• Ph II enrolment into port delivery study
completed; results expected in 2018
• Ph II results for anti-VEGF/Ang2 bispecific
antibody with dual MoA expected in 2018
Ophthalmology: Lucentis stabilized due to
prefilled syringe and new indications
Neuroscience: Ocrevus with excellent launch in
all treatment lines in RMS and PPMS
24 RMS=relapsing forms of multiple sclerosis; PPMS=primary progressive multiple sclerosis
0
100
200
300
400
Q1 17 Q2 17 Q3 17
US Europe International
CHFm Ocrevus Q3 2017
• Continued strong uptake in RMS and
PPMS (60/40) with some bolus in PPMS
• Market research indicates inroads in all
treatment lines in RMS
• RMS: 30% treatment naive/previously
discontinued vs. 70% switches from all
other approved medications
• Broad base of prescribers and high level
of US insurance coverage
Outlook 2017
• EU launch preparations on track
Recognition for innovation 2013-present
Two additional BTDs in hematology received
26
Rank Company #
1 Roche 18
2 Novartis 15
3 BMS 10
4 Merck 9
4 Pfizer 9
18 Breakthrough Therapy Designations
Source: http://www.focr.org/breakthrough-therapies as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine;
AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating
agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis
= BTDs in blood cancer
Late-stage hematology: Improving the standard
of care and extending into new indications
27 ¹ Datamonitor; incidence rates includes the 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); CLL=chronic lymphoid leukemia; DLBCL (aNHL)=diffuse
large B-cell lymphoma; iNHL=indolent non-hodgkin`s lymphoma; AML=acute myeloid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrome; ALL=acute
lymphoblastic leukemia; Venclexta in collaboration with AbbVie; Gazyva in collaboration with Biogen; Polatuzumab vedotin in collaboration with Seattle Genetics
Incidence rates (330,000 pts1)
Ph III 1L (CLL14)
Ph III R/R (MURANO)
Ph III
Ph III
Polatuzumab
vedotin
+
Ph II R/R
Ph III 1L (POLARIX) +
Ph III Idasanutlin
28
Hematology pipeline progress in 2017
12 molecules in combination testing
* Venclexta in collaboration with AbbVie; Polatuzumab vedotin in collaboration with Seattle Genetics; Cotellic in collaboration with Exelixis; ChK1i in collaboration with
Array BioPharma; NHL=non-hodgkin`s lymphoma; CLL=chronic lymphoid leukemia; MM=multiple myeloma; MDS=myelodysplastic syndrom; AML=acute myeloid
leukemia
= progress in 2017
2x
2x
29
APHINITY: Perjeta+Herceptin in HER2+ eBC
Priority review by the FDA
von Minckwitz et al, ASCO 2017; eBC=early breast cancer (adjuvant setting); HR=hormone receptor; * Target population for Herceptin in adjuvant breast cancer
(US & EU5); current Herceptin penetration ~95%; Source: Datamonitor and internal estimates
• Risk of recurrence or death reduced by 19% in all patients, 23% in node+ and 24% in HR- patients
62 patients
113 patients
221 patients
Emicizumab’s clinical development plan
HAVEN 3 results expected in Q4
inhibitor adults/adolescents (≥12 years old), qw
2015 2016 2017 2018
Q1 Q2 Q3 Q4
inhibitor children (0–11 years old), qw
non-inhibitor/inhibitor adults/adolescents, q4w
non-inhibitor adults/adolescents (≥12 years old), qw and q2w
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
HAVEN1
Non-
interventional
HAVEN2
HAVEN3
HAVEN4
152 patients
48 patients
Q4
H1 2018
30
Aiming to set new standards of care
Upcoming readouts for CIT & Hematology
32
Readouts:
(Q4 17 to Q2 18)
Most comprehensive lung cancer program
addressing all common backbones Lung
5 trials in non-squamous,
squamous & small cell
lung cancer
Among the leaders in renal cancer GU 1L RCC
First-in-class in colorectal cancer CRC 2/3L CRC
First-in-class in triple negative breast cancer Breast 1L TNBC
First-in-class in non-inhibitor hemophilia A Hemophilia Non-inhibitors and
monthly schedule
2017: Key late-stage news flow
Compound Indication Milestone
Regulatory
Alecensa 2L ALK+ NSCLC EU approval
Ocrevus RMS / PPMS US/EU launch
Tecentriq 1L cisplatin ineligible mUBC US approval
Tecentriq 2/3L NSCLC and 1/2L mUBC EU approval
Gazyva 1L FL (iNHL) US/EU filing
Actemra Giant cell arteritis US/EU approval
emicizumab Hemophilia A inhibitors US/EU filing
Phase III
readouts*
Perjeta + Herceptin Adjuvant HER2+ BC Ph III APHINITY
Alecensa 1L ALK+ NSCLC Ph III ALEX
Venclexta + Rituxan R/R CLL Ph III MURANO
Tecentriq + chemo/
Tecentriq + chemo + Avastin 1L NSCLC Ph III IMpower150
lampalizumab Geographic atrophy Ph III SPECTRI/CHROMA
emicizumab Hemophilia A non-inhibitors Ph III HAVEN3
33 Outcome studies are event-driven: timelines may change; mCNV=choroidal neovascularisation secondary to myopia
Additional YTD news flow:
• Lucentis: Approval in mCNV and diabetic retinopathy
• Rituxan Hycela for blood cancers approved and launched in the US
• Emicizumab: Positive interim results in pediatric inhibitors (HAVEN2)
• Gazyva 1L FL: EU approval achieved; FDA priority review (PDUFA date Dec 23)
• Alecensa 1L ALK+ NSCLC: Positive CHMP opinion and FDA priority review (PDUFA date Nov 30)
YTD Sept 2017: Diagnostics Division sales
Growth driven by CPS & Tissue Diagnostics
35 CER=Constant Exchange Rates
Underlying growth of Molecular Diagnostics excluding sequencing business: +4%
2017 2016
CHFm CHFm CHF CER
Diagnostics Division 8,798 8,365 5 5
Centralised and Point of Care Solutions 5,211 4,884 7 7
Diabetes Care 1,464 1,484 -1 -2
Molecular Diagnostics 1,388 1,345 3 3
Tissue Diagnostics 735 652 13 13
Change in %
North America
+1%
25% of divisional sales
Latin America
+11%
7% of divisional sales
Japan
+1%
4% of divisional sales EMEA1
+3%
40% of divisional sales
YTD Sept 2017: Diagnostics regional sales
Growth in all regions
Asia Pacific
+15%
24% of divisional sales
36
+18% growth in E7 countries2
1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates
YTD Sept 2017: Diagnostics Division highlights
Growth driven by Immunodiagnostics
37
0.0 2.0 4.0 6.0
Tissue
Diagnostics
Molecular
Diagnostics
Diabetes
Care
Centralised
and Point of
Care
Solutions
EMEA
North America
RoW
+13%
-2%
+7%
+3%
CHFbn
1
1 Underlying growth of Molecular Diagnostics excluding sequencing business: +4%
CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa
YoY CER growth
• Driven by immunodiagnostics (+13%);
clinical chemistry (+3%)
• Continued US pricing and reimbursement
pressures
• Virology (-2%); Blood screening (+4%)
• Advanced staining portfolio (+10%); primary
staining (+13%) and companion diagnostics
(+32%)
Implementing the fully integrated core laboratory
38
Connecting disciplines
(cobas 6800/8800, cobas
6500, cobas p 612)
Seamless workflow and
laboratory IT
(cobas connection modules)
Highest throughput analysers
(cobas e 801, cobas c 702)
Comprehensive menu
(Procalcitonin; Zika; MPX;
Syphilis)
Digitalised data
management
(Navify tumor board)
Continued momentum of cobas e 801 placements
Completion of serology blood screening panel
39 Note: Serology assays are CE marked according to Directive 98/79/EC. Test performance has been established according to the Common Technical Specifications
(CTS) for diagnostic use and for screening of blood donations
*only on cobas e 801, HIV combi PT is continued on cobas e 602, e 601 and e 411
cobas e 801
• Double throughput on same footprint
• 517 instruments placed in 28 markets
Blood screening assays
HIV Duo*
Anti-HCV II
HBsAg II
Anti-HBc II
Anti-HBs II
HTLV-I/II
Syphilis
CMV lgG
CMV IgM
Chagas
* Launched in 2017
Targeting medication to atrial fibrillation patients
GDF-15 test predicts individual bleeding-risk
40
• 33 million people with atrial fibrillation globally,
at increased risk of stroke
• Today 50% of patients receive no stroke
prevention treatment due to perceived bleeding
risk
• GDF-15 informs on individual bleeding risks
and allows for more targeted treatment
decisions
Figure 3: Importance of variables considered for inclusion in the ABC-bleeding score (ARISTOTLE
derivation cohort; n=14,537) as assessed by Wald Regression. Adapted from Hijazi 2016.
1 The improved prognostic value of the ABC bleeding risk score is recognized in the 2016 European Society of Cardiology Guidelines
for the management of atrial fibrillation
FDA approval of first commercial Zika IVD test
Expanding our leading blood screening portfolio
41
cobas 6800/8800 Systems: 313 instruments placed in 33 markets***
MAY 2015
Zika outbreak confirmed in Brazil
DEC 2015
Locally-acquired Zika cases reported in Puerto Rico
FEB 2016
WHO declares international Public Health Emergency
MAR 2016
cobas® Zika test receives IND* status from FDA
APR 2016
Screening of Puerto Rico donations with cobas Zika IND*
JUL 2016
Transmission of Zika virus reported in Miami, FL
AUG 2016
FDA mandates US screening for Zika virus
APR 2017
BLA** submission to FDA for cobas®
Zika
OCT 2017
FDA approval of cobas® Zika test
*IND: Investigational New Device
**BLA: Biologics License Application
***Status YTD August 2017
Launch of NAVIFY tumor board
Entering digital information systems market
42
• Oncology care team workflow and decision support tool
• Aggregates patient data from multiple sources into a dashboard
• Improved team collaboration and efficiency, reduces errors
• Auditable decision tracking
• Patient data stored and accessed securely
Area Product Market
Instruments/
Devices
Central
Laboratory
cobas 8000 <e 801> – High throughput immunochemistry analyser
CCM High Speed – cobas connection module (CCM) for up to 6000 samples/hour
US
WW
Coagulation
Testing cobas t 511 / t 711 – Medium and high volume coagulation systems EU
Point of Care CoaguChek Vantus – Hand-held coagulation monitoring system for Patient Self-
Testing US
Diabetes Care Accu-Chek Instant bG System – Effortless, accurate and affordable bG system
for price sensitive markets EU
Tests/
Assays
HPV cobas HPV – Next generation HPV DNA test leveraging 68/8800 Automation to detect
14 hrHPV with simultaneous detection of genotypes 16 and 18
CINtec Histology – Diagnostic component of the Roche Cervical Cancer portfolio
EU
US
Virology cobas HIV 1&2 Qual – For use on the cobas 6800/8800 Systems; for diagnosis of acute
HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection EU
Sequencing AVENIO ctDNA panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted
panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)
EU/US
cobas Liat
cobas Liat C.diff – Qualitative IVD test, that utilizes real-time PCR, for the direct
detection of the tcdB gene of toxigenic C. difficile in unformed stool specimens
cobas Liat MRSA/SA – Qualitative IVD test, that utilizes real-time PCR, for the direct
detection of MRSA and Staphylococcus aureus DNA from nasal swabs
EU
EU
Women’s Health AMH – Immunoassay for the in vitro quantitative determination of anti-Mullerian hormone
(AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics
US
Companion
Diagnostics
PD-L1 (SP142) for Bladder Cancer* – complementary diagnostic for Tecentriq
PD-L1 (SP142) for NSCLC* – complementary diagnostic for Tecentriq
EU
EU
Key launch list 2017
43 * = Achieve commercial readiness, dependent on Pharma label and approval
• Strong underlying Group sales growth, particularly in the US (+8%) and International
(+7%) regions
• +5% growth in both divisions
YTD Sept 2017: Highlights
45
Sales
• Negative impact from Other Europe currencies and JPY offset by Lat-Am currencies and
USD
Currency impact
All growth rates at Constant Exchange Rates (CER)
Group sales YTD Sept 2017
Sales increase driven by US and Diagnostics Division
46 Absolute values and growth rates at Constant Exchange Rates (CER) 1 average Full Year 2016 to average YTD Sept 2017 Fx
+1,970
+1,361
-41
+1,929
-107+208 +54
+454
United States Europe Intl. Japan Diagnostics
Division
Group Fx Group
CHF
Pharma Division+5%
+10% -2% +4% +2% +5% +5% +5%
1
CER
sales
growth
YTD Sep
2017
vs.
YTD Sep
2016
Exchange rate impact on sales growth
Negative impact from Other Europe currencies and JPY offset by Lat-Am currencies and USD
CER=Constant Exchange Rates
CHF
sales
growth
YTD Sep
2017
vs.
YTD Sep
2016
+5.2% +5.1%
+0.2p +0.2p +0.1p 0.0p -0.1p -0.2p -0.3p
CER Lat-Am USD Other EUR As-Pac JPY Other
Europe
CHF
47
1.01 1.00 1.00 1.00 0.99 0.97 0.96 0.97 0.96 0.97 0.97 0.97
1.00 0.99
0.98
0.98 0.99
0.98 0.98
0.99
J F M A M J J A S O N D
1.07 1.07 1.07 1.07 1.09 1.09 1.10 1.14 1.15 1.14 1.14 1.14
1.07 1.08 1.09
1.11 1.10 1.10 1.09
1.09
J F M A M J J A S O N D
Low currency impact expected in 2017
Assuming the 30 September 2017 exchange
rates remain stable until end of 2017,
2017 impact is expected to be (%p):
CHF / USD
CHF / EUR
+1%
Average YTD 2016
1% 1% 0% 0%
-2% -2% 0% +1%
Assumed
average YTD
2017
Monthly avg fx rates 2017 Fx rates at 30 Sep 2017
48
Q1 HY Sep
YTD
FY
Sales 0 0 0
Core
operating
profit
0
Core EPS 0
2017 outlook raised at HY
49
Group sales growth1 Mid-single digit
Core EPS growth1 Broadly in line with sales growth
Dividend outlook Further increase dividend in Swiss francs
1 At Constant Exchange Rates (CER)
New to phase I New to phase II New to phase III New to registration
Changes to the development pipeline
Q3 2017 update
Removed from phase I Removed from phase II Removed from phase III Removed from registration
3 NMEs:
RG6160 NME – multiple myeloma
RG6147 NME – geographic
atrophy
RG7945 NME - glaucoma
1 AI:
RG3616 Erivedge + ruxolitinib –
myelofibrosis
1 NME transitioned from Ph II:
RG6206 anti-myostatin
adnectin – DMD
1 AI:
RG7446 Tecentriq + paclitaxel –
1L TNBC
1 AI following filing in US/EU:
RG1273 Perjeta + Herceptin –
HER2+ BC adj
1 AI following filing in US:
RG7204 Zelboraf – Erdheim-
Chester disease
3 NMEs:
RG3637 lebrikizumab – atopic
dermatitis (out-licensed)
RG7745 Flu A MAb – influenza A
RG7221 vanucizumab - mCRC
Status as of October 19, 2017
2 AIs:
RG1273 Perjeta + Herceptin -
1L HER2+ gastric cancer
RG7204 Zelboraf – BRAFm
melanoma adj
1 NME following EU approval:
RG7446 Tecentriq – 2L mUC
2 AIs following EU approval:
RG1569 Actemra – giant cell
arteritis
RG7446 Tecentriq – 2L+ NSCLC
1 CHU following Japan approval:
CHU Actemra – Takayasu arteritis
and giant cell arteritis
1 NME transitioned from Ph I:
RG6100 Tau MAb - Alzheimer’s
disease
1 AI:
RG7388 idasanutlin -
polycythemia vera
51
RG6026 CD20 TCB heme tumors
RG6047 SERD (2) ER+ (HER2-neg) mBC
RG6058 TIGIT ± Tecentriq solid tumors
RG6114 mPI3K alpha inh HR+ BC
RG6146 BET inh combos solid + heme tumors
RG6160 - multiple myeloma
RG6180 personalized cancer vaccine ± T oncology
RG6185 pan-RAF inh + Cotellic solid tumors
RG7155 emactuzumab + Tecentriq solid tumors
emactuzumab + selicrelumab solid tumors
RG7159 anti-CD20 combos heme tumors
RG7386 FAP-DR5 biMAb solid tumors
RG7421 Cotellic + Zelboraf + T melanoma
Cotellic + T 2L BRAF WT mM
RG7446
Tecentriq solid tumors
Tecentriq NMIBC
T-based Morpheus platform solid tumors
T + Avastin + Cotellic 2/3L CRC
T ± Avastin ± chemo HCC, GC, PaC
T ± Avastin ± chemo solid tumors
T + Cotellic solid tumors
T + ipi/IFN solid tumors
T + Tarceva/Alecensa NSCLC
T + anti-CD20 combos heme tumors
T ± lenalidomide ± daratumumab MM
T + K/HP HER2+ BC
T + HMA MDS
T + radium 223 mCRPC
T + guadecitabine AML
T + rucaparib ovarian ca
RG7461 FAP IL2v FP combos solid tumors
RG7601 Venclexta + Cotellic/idasanutlin AML
Venclexta ± azacitadine r/r MDS
RG7741 ChK1 inh solid tumors
RG7802 CEA TCB ± Tecentriq solid tumors
RG7813 CEA IL2v FP* + Tecentriq solid tumors
RG7828 CD20 TDB ± Tecentriq heme tumors
RG7876 selicrelumab (CD40) + T solid tumors
selicrelumab + vanucizumab solid tumors
RG7882 MUC16 ADC ovarian ca
RG7986 ADC r/r NHL
CHU Raf/MEK dual inh solid tumors
CHU glypican-3/CD3 biMAb solid tumors
RG6069 anti-fibrotic agent fibrosis
RG6107 C5 inh MAb PNH
RG7835 - autoimmune diseases
RG7880 IL-22Fc inflammatory diseases
RG7990 - asthma
RG6004 HBV LNA HBV
RG6080 nacubactam bact.infections
RG7854 TLR7 agonist (3) HBV
RG7861 anti-S. aureus TAC infectious diseases
RG7907 HBV Capsid (2) HBV
RG7992 FGFR1/KLB MAb metabolic diseases
RG6000 - ALS
RG6029 Nav1.7 inh (2) pain
RG7203 PDE10A inh schizophrenia
RG7906 - psychiatric disorders
IONIS ASO Huntington’s
RG6147 - geographic atrophy
RG7945 - glaucoma
CHU PTH1 recep. ago hypoparathyroidism
CHU - hyperphosphatemia
RG3502 Kadcyla + Tecentriq 2L HER2+ mBC
RG7388 Idasanutlin§ polycythemia vera
RG7421 Cotellic + Tecentriq ± taxane TNBC
RG7440 ipatasertib 1L TNBC
ipatasertib TNBC neoadj
RG7596 polatuzumab vedotin DLBCL
RG7601
Venclexta + Rituxan DLBCL
Venclexta + Rituxan r/r FL
Venclexta + azacitadine 1L MDS
RG7604 taselisib + letrozole (HER2-neg) BC neoadj
RG7686 codrituzumab liver cancer
RG3637 lebrikizumab ± Esbriet (NME) IPF
RG6125 Cadherin-11 MAb RA
RG6149 ST2 MAb asthma
RG7159 obinutuzumab lupus
RG7625 Cat-S antag autoimmune diseases
RG7845 BTK inh RA, lupus, CSU
CHU nemolizumab** pruritus in dialysis patients
PRO VAP-1 inh inflammatory disease
NOV TLR4 MAb autoimmune diseases
RG6152 CAP endonuclease inh influenza
CHU URAT1 inh gout
RG1662 basmisanil CIAS, post-stroke recovery
RG6083 olesoxime SMA
RG6100 Tau MAb§ Alzheimer’s
RG7314 V1a receptor antag autism
RG7916 SMN2 splicer(2) SMA
RG7935 α-synuclein MAb Parkinson's
RG3645 ranibizumab PDS wAMD
RG7716 VEGF-ANG2 biMAb wAMD, DME New Molecular Entity (NME) RG-No Roche/Genentech
Additional Indication (AI) CHU Chugai managed
Oncology IONIS IONIS managed
Immunology PRO Proximagen managed
Infectious Diseases NOV Novimmune managed
CardioMetabolism *INN: cergutuzumab amunaleukin
Neuroscience **out-licensed to Galderma and Maruho
Ophthalmology for atopic dermatitis
Other § FPI expected Q4 2017
T=Tecentriq; TCB=T cell bispecific;
TDB=T cell dependent bispecific
Phase I (40 NMEs + 23 AIs)
Status as of October 19, 2017
Phase II (19 NMEs + 11 AIs)
Roche Group development pipeline
52
RG3502 Kadcyla HER2+ BC adj
Kadcyla + Perjeta HER2+ BC adj
RG6013 emicizumab hemophilia A w/o FVIII inh
emicizumab Q4W hemophilia A
RG7388 idasanutlin + chemo AML
RG7440 ipatasertib + chemo 1L CRPC
RG7421 Cotellic + Zelboraf + T BRAFm melanoma
RG7446
Tecentriq NSCLC adj
Tecentriq MIBC adj
Tecentriq Dx+ 1L sq + non-sq SCLC
Tecentriq RCC adj
T + nab-paclitaxel 1L non-sq NSCLC
T + chemo+ Avastin 1L ovarian cancer
T + chemo + Avastin 1L non-sq NSCLC
T + chemo + pemetrexed 1L non-sq NSCLC
T + nab-paclitaxel 1L sq NSCLC
T + paclitaxel 1L TNBC
T + nab-paclitaxel 1 LTNBC
T + nab-paclitaxel TNBC neoadj
T + Avastin RCC
T + Cotellic 3L CRC
T ± chemo 1L mUC
T + chemo 1L extensive stage SCLC
T + enzalutamide CRPC
RG7601
Venclexta + Rituxan r/r CLL
Venclexta + Gazyva 1L CLL
Venclexta + bortezomib MM
Venclexta + HMA 1L AML
RG7604 taselisib + fulvestrant ER+(HER2-neg) mBC
RG105 MabThera pemphigus vulgaris
RG1569 Actemra systemic sclerosis
RG7413 etrolizumab ulcerative colitis
etrolizumab Crohn’s
RG1450 gantenerumab Alzheimer’s
RG6168 satralizumab (IL-6R MAb) NMO
RG6206 anti-myostatin adnectin DMD
RG7412 crenezumab Alzheimer’s
RG7417 lampalizumab geographic atrophy
RG3645 Lucentis 0,3mg PFS1 DME/DR
RG435 Avastin1 GBM
RG1273 Perjeta + Herceptin HER2+ BC adj
RG6013 emicizumab hemophilia A FVIII inh
RG7159 Gazyva2 1L FL
RG7204 Zelboraf1 Erdheim-Chester disease
RG7853 Alecensa 1L ALK+ NSCLC
RG1594 Ocrevus3 PPMS + RMS
Roche Group development pipeline
1 US only
2
3 Approved in US
Approved in EU
Phase III (9 NMEs + 30 AIs) Registration (2 NMEs + 5 AIs)
Status as of October 19, 2017
New Molecular Entity (NME) RG-No Roche/Genentech
Additional Indication (AI) CHU Chugai managed
Oncology RG1569 Branded as RoActemra (EU)
Immunology RG7159 Branded as Gazyvaro (EU)
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other T=Tecentriq
53
NME submissions and their additional indications
Projects currently in phase II and III
RG6013 emicizumab ✓
hemophilia A FVIII inh
pediatrics and adults
RG7604 taselisib+fulvestrant
PIK3CAmut ER+ (HER2-neg) mBC
RG6013
emicizumab hemophilia A FVIII non-inh
RG6013 emicizumab
hemophilia A, Q4W
RG7388 idasanutlin
polycythemia vera
RG7440 ipatasertib
1L CRPC
RG7440 ipatasertib
1L TNBC
RG7440 ipatasertib
TNBC neoadj
RG7596
polatuzumab vedotin DLBCL
RG7604 taselisib + letrozole
ER+ (HER2-neg) BC neoadj
RG1450 gantenerumab
Alzheimer‘s
RG1662
basmisanil CIAS, post-stroke
recovery
RG6083 olesoxime
SMA
RG6100 Tau MAb
Alzheimer’s
RG6206
anti-myostatin adnectin
DMD
RG7314 V1 receptor antag
autism
RG7412 crenezumab Alzheimer’s
RG7916 SMN2 splicer(2)
SMA
RG7935 α-synuclein MAb
Parkinson’s
RG7716 VEGF/ANG2 biMAb
wAMD/DME
RG6152
CAP endo- nuclease inh
influenza
RG3637
lebrikizumab ± Esbriet
IPF
RG6125 Cadherin-11 MAb
RA
RG6149 ST2 MAb Asthma
RG7413 etrolizumab
ulcerative colitis
RG7413 etrolizumab
Crohn’s
RG7625 Cat S antag
autoimmune diseases
RG7845 BTK inh
autoimmune diseases
2018 2017 2020 and beyond 2019
RG6168 satralizumab
IL-6R MAb, SA237 neuromyelitis optica
RG7388 idasanutlin
AML
New Molecular Entity (NME) CardioMetabolism
Additional Indication (AI) Neuroscience
Oncology Ophthalmology
Immunology Other
Infectious Diseases
✓ Indicates a submission which has occurred with regulatory action pending
Unless stated otherwise submissions are planned to occur in US and EU
Status as of October 19, 2017
54
AI submissions for existing products
Projects currently in phase II and III
✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
2018 2017 2020 and beyond 2019
RG3645
Lucentis 0.3mg PFS (US)
DME/DR
RG435 Avastin (US) ✓
GBM
RG1273 Perjeta + Herceptin ✓
HER2+ BC adj.
RG7159 Gazyva (US) ✓
1L FL
RG7204 Zelboraf (US) ✓
Erdheim-Chester disease
RG7601 Venclexta + Rituxan
r/r CLL
RG7853 Alecensa ✓
1L ALK+ NSCLC
RG105 MabThera
pemphigus vulgaris
RG1569 Actemra
systemic sclerosis
RG7446
Tecentriq + chemo + Avastin
1L non-sq NSCLC
RG7446
Tecentriq + nab-paclitaxel
1L sq NSCLC
RG7446
Tecentriq + nab-paclitaxel
1L non-sq NSCLC
RG7446
Tecentriq + chemo + pemetrexed
1L non-sq NSCLC
RG7446 Tecentriq + chemo
1L extens. stage SCLC
RG7446 Tecentriq + Avastin
RCC
RG7446
Tecentriq + nab-paclitaxel
TNBC
RG3502 Kadcyla + Tecentriq
2L Her2+ mBC
RG3502 Kadcyla + Perjeta
HER2+ BC adj.
RG3502 Kadcyla
HER2+ BC adj.
RG7601 Venclexta + Rituxan
r/r FL
RG7601 Venclexta + Rituxan
DLBCL
RG7601 Venclexta + HMA
1L AML
RG7601 Venclexta + HMA
1L MDS
RG7421
Cotellic + Tecentriq ± taxane
TNBC
RG3645 ranibizumab PDS
wAMD
RG7159 obinutuzumab
lupus nephritis
RG7446 Tecentriq ± chemo
1L mUC
RG7446 Tecentriq NSCLC adj
RG7446 Tecentriq MIBC adj
RG7446
Tecentriq + enzalutamide
CRPC
RG7446 Tecentriq RCC adj
RG7446
Tecentriq + chemo + Avastin
1L ovarian cancer
New Molecular Entity (NME) CardioMetabolism
Additional Indication (AI) Neuroscience
Oncology Ophthalmology
Immunology Other
Infectious Diseases
RG7446 Tecentriq + Cotellic
3L CRC
RG7421
Cotellic + Tecentriq + Zelboraf
BRAFmut melanoma
RG7446
Tecentriq 1L non-sq + sq NSCLC (Dx+)
RG7446
Tecentriq+ nab-paclitaxel
TNBC neoadj
RG7446 Tecentriq + paclitaxel
1L TNBC
RG7601 Venclexta + Gazyva
1L CLL
RG7601
Venclexta + bortezomib
MM
Status as of October 19, 2017
55
EU Japan-Chugai US
RG105
Rituxan Hycela™ (SC)
NHL/CLL
June 2017
RG7446
Tecentriq 1L bladder cancer, cis-ineligible
April 2017
RG1569
Actemra giant cell arteritis
May 2017
RG1569
Actemra CRS
August 2017
RG1594
Ocrevus
PPMS & RMS
March 2017
RG3645
Lucentis mCNV
January 2017
RG3645
Lucentis diabetic retinopathy w/o DME
April 2017
RG435
Avastin GBM
Filed February 2017
RG1273
Perjeta + Herceptin HER2+ BC adj Filed July 2017
RG6013
emicizumab hemophilia A FVIII inh (pediatrics and adults)
Filed June 2017
RG7159
Gazyva
follicular lymphoma 1L
Filed June 2017
RG7204
Zelboraf
Erdheim-Chester disease
Filed June 2017
RG7853
Alecensa 1L ALK+ NSCLC Filed May 2017
RG1273
Perjeta + Herceptin HER2+ BC adj
Filed August 2017
RG6013
emicizumab hemophilia A FVIII inh (pediatrics and adults)
Filed June 2017
RG7853
Alecensa
1L ALK+ NSCLC
Filed March 2017
RG1594
Ocrevus
PPMS & RMS
Filed April 2016
Approved
Pending Approval
RG6013
emicizumab hemophilia A FVIII inh (pediatrics and adults)
Filed July 2017
RG7446
Tecentriq
2L+ NSCLC
Filed February 2017
RG435
Avastin
chemo backbone extension
rel. OC Pt-sensitive
June 2017
RG7159
Gazyva
1L follicular lymphoma
September 2017
RG7446
Tecentriq
mUC 2L
September 2017
RG7446
Tecentriq
2L+ NSCLC
September 2017
RG7853
Alecensa
2L ALK+ NSCLC
February 2017
RG1569
Actemra
giant cell arteritis
September 2017
New Molecular Entity (NME) CardioMetabolism
Additional Indication (AI) Neuroscience
Oncology Ophthalmology
Immunology Other
Infectious Diseases
CHU
Actemra
Takayasu arteritis and
giant cell arteritis
August 2017
56
Status as of October 19, 2017
Major granted and pending approvals 2017
Roche Group development pipeline
Combinations
RG6058 TIGIT ± Tecentriq solid tumors
RG6146 BET inh combos solid + heme tumors
RG6180 personalized cancer vaccine ± T oncology
RG6185 pan-RAF inh + Cotellic solid tumors
RG7155 emactuzumab + Tecentriq solid tumors
emactuzumab + selicrelumab solid tumors
RG7159 anti-CD20 combos heme tumors
RG7421 Cotellic + Zelboraf + T melanoma
Cotellic + T BRAF WT mM2L
RG7446
T-based Morpheus platform solid tumors
T + Avastin + Cotellic 2/3L CRC
T ± Avastin ± chemo HCC, GC, PaC
T ± Avastin ± chemo solid tumors
T + Cotellic solid tumors
T + ipi/IFN solid tumors
T + Tarceva/Alecensa NSCLC
T + anti-CD20 combos heme tumors
T ± lenalidomide ± daratumumab MM
T + K/HP HER2+ BC
T + HMA MDS
T + radium 223 mCRPC
T + guadecitabine AML
T + rucaparib ovarian ca
RG7461 FAP IL2v FP combos solid tumors
RG7601 Venclexta + Cotellic/idasanutlin AML
Venclexta ± azacitidine r/r MDS
RG3502 Kadcyla + Tecentriq 2L HER2+ mBC
RG7421 Cotellic + Tecentriq ± taxane TNBC
RG7601
Venclexta + Rituxan DLBCL
Venclexta + Rituxan r/r FL
Venclexta + azacitidine 1L MDS
RG7604 taselisib + letrozole (HER2-) BC neoadj
RG3637 lebrikizumab ± Esbriet (NME) IPF
Phase II (1 NME + 6 AIs)
RG3502 Kadcyla + Perjeta HER2+ BC adj
RG7388 idasanutlin + chemo AML
RG7440 ipatasertib + chemo 1L CRPC
RG7421 Cotellic + Zelboraf + T BRAFm melanoma
RG7446
T + nab-paclitaxel 1L non-sq NSCLC
T + chemo + Avastin 1L ovarian cancer
T + chemo + Avastin 1L non-sq NSCLC
T + chemo + pemetrexed 1L non-sq NSCLC
T + nab-paclitaxel 1L sq NSCLC
T + nab-paclitaxel 1L TNBC
T + nab-paclitaxel TNBC neoadj
T + Cotellic 3L CRC
T + Avastin RCC
T ± chemo 1L mUC
T + chemo 1L extens. stage SCLC
T + enzalutamide CRPC
T + paclitaxel 1L TNBC
RG7601
Venclexta + Rituxan r/r CLL
Venclexta + Gazyva 1L CLL
Venclexta + bortezomib MM
Venclexta + HMA 1L AML
RG7604 taselisib + fulvestrant ER+ (HER2-neg) mBC
Phase III (3 NMEs + 19 AIs)
New Molecular Entity (NME) RG-No Roche/Genentech
Additional Indication (AI) CHU Chugai managed
Oncology *INN: cergutuzumab amunaleukin
Immunology T=Tecentriq; TCB=T cell bispecific
TDB=T cell dependent bispecific
Status as of October 19, 2017
RG1273 Perjeta + Herceptin HER2+ BC adj
Registration (1 AI)
57
Phase I (10 NMEs + 21 AIs)
RG7828 CEA TCB ± Tecentriq solid tumors
RG7813 CEA IL2v FP* + Tecentriq solid tumors
RG7828 CD20 TDB ± Tecentriq heme tumors
RG7876 selicrelumab (CD40) + T solid tumors
selicrelumab + vanucizumab solid tumors
Cancer immunotherapy pipeline overview
RG6026 CD20 TCB hematopoietic tumors
RG6058 TIGIT ± Tecentriq solid tumors
RG6160 - multiple myeloma
RG6180 personalized cancer vaccine ± T oncology
RG7155 emactuzumab + Tecentriq solid tumors
emactuzumab + selicrezumab solid tumors
RG7421 Cotellic + Zelboraf + T melanoma
Cotellic + T BRAF WT mM2L
RG7446
Tecentriq solid tumors
Tecentriq NMIBC
T-based Morpheus platform pancreatic ca
T + Cotellic ± Avastin 2/3L CRC
T ± Avastin ± chemo HCC, GC, PaC
T ± Avastin ± chemo solid tumors
T + Cotellic solid tumors
T + ipi/IFN solid tumors
T + Tarceva/Alecensa NSCLC
T + anti-CD20 multiple combos lymphoma
T ± lenalidomide ± daratumumab MM
T + K/HP HER2+ BC
T + HMA MDS
T + radium 223 mCRPC
T + guadecitabine AML
T + rucaparib ovarian ca
RG7461 FAP IL2v FP + Tecentriq ± Avastin RCC
RG7802 CEA TCB ± Tecentriq solid tumors
RG7813 CEA IL2v FP* + Tecentriq solid tumors
RG7828 CD20 TDB ± Tecentriq solid tumors
RG7876 selicrelumab (CD40) + T solid tumors
selicrelumab + vanucizumab solid tumors
RG3502 Kadcyla + Tecentriq 2L HER2+ mBC
RG7421 Cotellic + Tecentriq ± taxane TNBC
IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma
SNDX** Tecentriq + entinostat TNBC
RG7421 Cotellic + Zelboraf + T BRAFm melanoma
RG7446
Tecentriq NSCLC adj
Tecentriq MIBC adj
Tecentriq Dx+ 1L sq + non-sq SCLC
Tecentriq RCC adj
T + nab-paclitaxel 1L non-sq NSCLC
T + chemo + Avastin 1L ovarian cancer
T + chemo + Avastin 1L non-sq NSCLC
T + chemo + pemetrexed 1L non-sq NSCLC
T + nab-paclitaxel 1L sq NSCLC
T + nab-paclitaxel 1L TNBC
T + nab-paclitaxel TNBC neoadj
T + Avastin RCC
T + Cotellic 3L CRC
T ± chemo 1L mUC
T + chemo 1L extensive stage SCLC
T + enzalutamide CRPC
T + paclitaxel 1L TNBC
** External collaborations: HALO – Halozyme PEGPH20; INCY- Incyte IDO inh; CLDX - Celldex CD27 MAb; CRVS – Corvus ADORA2A antag; KITE – Kite KTE-C19; AMGN – Amgen oncolytic virus; JNJ – Janssen CD38 MAb; CLVS – Clovis PARP inh; EPZM – Epizyme EZH2 inh; BLRX - BioLine Rx CXCR4 antag; IMDZ – Immune Design CMB305; SNDX – Syndax HDAC inh
New Molecular Entity (NME) RG-No Roche/Genentech
Additional Indication (AI) *INN: cergutuzumab amunaleukin
Oncology T=Tecentriq; TCB=T cell bispecific
TDB=T cell dependent bispecific
RG7446 T-based Morpheus pancreatic cancer
T-based Morpheus gastric cancer
AMGN** Tecentriq + talimogene laherp TNBC, CRC
BLRX** Tecentriq + BL-8040 AML, solid tumors
CLDX** Tecentriq + varlilumab solid tumors
CLVS** Tecentriq + rucaparib ovarian ca
CRVS** Tecentriq + CPI-444 solid tumors
EPZM** Tecentriq + tazemetostat r/r DLBCL
HALO** Tecentriq + PEGPH20 CCC, GBC
INCY** Tecentriq + epacadostat solid tumors
JNJ** Tecentriq ± daratumumab solid tumors
KITE** Tecentriq + KTE-C19 r/r DLBCL
Phase I (10 NMEs + 30 AIs)
Phase III (18 AIs)
Phase II (4 AIs)
MORPHEUS Platform - Phase Ib/II (2 AIs)
Status as of October 19, 2017
58